Genocea Biosciences Secures Debt Facility From Hercules Technology Growth Capital Of Up To $27 Million
CAMBRIDGE, Mass--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.